Successful rechallenge of bevacizumab after grade 4 bevacizumab induced hypertension in a case of carcinoma ovary, is rechallenging an option? - A Rare case report
GCRI, Medical Oncology, GCRI, Ahmedabad, Gujarat, India.
Case Study
GSC Biological and Pharmaceutical Sciences, 2022, 18(03), 030–034.
Article DOI: 10.30574/gscbps.2022.18.3.0161
Publication history:
Received on 07 Jully 2021; revised on 21 February 2022; accepted on 23 February 2022
Abstract:
Treatment of multi-resistant ovarian cancer is palliative. Patient after receiving multiple lines of chemotherapy are neither in good PS nor have good compliance to receive further toxic treatment.
Bevacizumab is a vascular endothelial growth factor which inhibit angiogenesis. Bevacizumab is generally used in combination with chemotherapy. Due to its low toxicity profile, improvement in progression free survival (PFS), easy availability in resources limited settings, it is a good adjunct to more toxic and costly regimens. Development of hypertension is one of the most common adverse event of bevacizumab.
We present a case of patient of metastatic carcinoma ovary, who developed grade 4 hypertension post 1st cycle of bevacizumab for which treatment was withheld. After control of blood pressure, she was rechallenged with bevacizumab and patient did not had any hypertensive episode and is doing well at present.
Keywords:
Carcinoma Ovary; Chemo Resistant; Biologics VEGF; Metastatic; Grade 4 Hypertension.
Full text article in PDF:
Copyright information:
Copyright © 2022 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
